Merck & Co., Inc. (NYSE:MRK) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Merck & Co., Inc. (NYSE:MRK) from a hold rating to a buy rating in a report issued on Saturday.

A number of other equities analysts also recently issued reports on MRK. Deutsche Bank Aktiengesellschaft upgraded Merck & Co., Inc. from a “hold” rating to a “buy” rating and set a $150.00 price target for the company in a research note on Friday, February 13th. The Goldman Sachs Group raised their target price on Merck & Co., Inc. from $92.00 to $120.00 and gave the company a “buy” rating in a report on Tuesday, December 2nd. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Merck & Co., Inc. in a research report on Monday, December 29th. Cantor Fitzgerald upped their price target on Merck & Co., Inc. from $116.00 to $120.00 and gave the stock a “neutral” rating in a report on Wednesday, February 4th. Finally, Guggenheim increased their price target on Merck & Co., Inc. from $122.00 to $140.00 and gave the company a “buy” rating in a research report on Friday, February 6th. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and seven have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $127.13.

Merck & Co., Inc. Stock Performance

MRK opened at $117.99 on Friday. The company has a current ratio of 1.54, a quick ratio of 1.30 and a debt-to-equity ratio of 0.89. The company’s fifty day moving average price is $116.83 and its two-hundred day moving average price is $102.29. Merck & Co., Inc. has a 1-year low of $73.31 and a 1-year high of $125.14. The company has a market cap of $291.71 billion, a price-to-earnings ratio of 16.21, a PEG ratio of 2.31 and a beta of 0.27.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings data on Tuesday, February 3rd. The company reported $2.04 earnings per share for the quarter, beating analysts’ consensus estimates of $2.01 by $0.03. The firm had revenue of $16.40 billion for the quarter, compared to analyst estimates of $16.19 billion. Merck & Co., Inc. had a net margin of 28.08% and a return on equity of 44.57%. The business’s quarterly revenue was up 5.0% compared to the same quarter last year. During the same period last year, the firm earned $1.72 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. On average, analysts expect that Merck & Co., Inc. will post 9.01 EPS for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 7th. Shareholders of record on Monday, March 16th will be paid a $0.85 dividend. The ex-dividend date is Monday, March 16th. This represents a $3.40 annualized dividend and a yield of 2.9%. Merck & Co., Inc.’s dividend payout ratio (DPR) is 46.70%.

Insider Activity

In related news, CMO Chirfi Guindo sold 20,000 shares of the stock in a transaction that occurred on Thursday, February 5th. The stock was sold at an average price of $121.88, for a total transaction of $2,437,600.00. Following the completion of the sale, the chief marketing officer directly owned 80,615 shares of the company’s stock, valued at approximately $9,825,356.20. This trade represents a 19.88% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Jennifer Zachary sold 121,573 shares of Merck & Co., Inc. stock in a transaction on Monday, February 9th. The stock was sold at an average price of $119.15, for a total value of $14,485,422.95. Following the sale, the executive vice president owned 68,916 shares in the company, valued at $8,211,341.40. This trade represents a 63.82% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 320,176 shares of company stock worth $38,281,735. Corporate insiders own 0.09% of the company’s stock.

Institutional Investors Weigh In On Merck & Co., Inc.

Several large investors have recently made changes to their positions in the business. Kingdom Financial Group LLC. bought a new stake in Merck & Co., Inc. in the fourth quarter worth about $25,000. Darwin Wealth Management LLC boosted its stake in Merck & Co., Inc. by 237.4% in the third quarter. Darwin Wealth Management LLC now owns 307 shares of the company’s stock valued at $26,000 after acquiring an additional 216 shares during the last quarter. Abound Financial LLC bought a new position in shares of Merck & Co., Inc. during the 4th quarter valued at approximately $26,000. Prosperity Bancshares Inc bought a new position in shares of Merck & Co., Inc. during the 4th quarter valued at approximately $26,000. Finally, Kilter Group LLC purchased a new stake in shares of Merck & Co., Inc. during the 2nd quarter worth approximately $27,000. 76.07% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Late‑stage cholesterol pill delivered large LDL cuts (≈64.6%) and met its head‑to‑head primary endpoint — a potential new blockbuster oral option for lowering “bad” cholesterol that could materially diversify revenue beyond oncology. Merck’s drug reduced bad cholesterol by 64.6% in late-stage trial
• Positive Sentiment: Phase 2 CADENCE results for WINREVAIR (sotatercept-csrk) showed proof‑of‑concept in combined post‑ and precapillary pulmonary hypertension with HFpEF — opens a foothold in a hard heart‑failure segment and supports pipeline value. How Investors May Respond To Merck (MRK) WINREVAIR Phase 2 Success In Tough Heart Failure Segment
• Positive Sentiment: Royal Bank of Canada reaffirmed an “outperform” and a $142 price target — a sizable upside vs. current levels that can support investor confidence and buying interest. Benzinga coverage
• Neutral Sentiment: Retail and media attention (e.g., Jim Cramer’s “stay the course” call) has driven momentum into Merck stock over recent months; that attention can amplify swings but is not a fundamental catalyst. Merck (MRK) Shares Up Significantly Since Jim Cramer Advised to “Stay the Course”
• Neutral Sentiment: Industry reports list Merck as a major player in the growing cutaneous squamous cell carcinoma market — underscores long‑term TAM but not an immediate stock driver. Cutaneous Squamous Cell Carcinoma (cSCC) Market Rises to $8.33 Billion
• Neutral Sentiment: New FY2026 earnings estimates and coverage updates are circulating (Erste Group Bank note) — watch revisions for guidance confirmation versus management’s FY2026 EPS range. FY2026 Earnings Estimate for MRK Issued By Erste Group Bank
• Negative Sentiment: Analysis flags an upcoming Keytruda patent cliff and Merck’s aggressive M&A push to refill the revenue gap — a strategic risk that could pressure sentiment if deal execution or integration falls short. Merck: Aggressive M&A Efforts To Prepare For A Keytruda Patent Cliff

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.